Skip to search formSkip to main contentSkip to account menu

olomoucine II

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Cyclin-dependent kinase inhibitors (CDKi) have high potential applicability in anticancer therapy, but various aspects of their… 
2013
2013
Purine cyclin-dependent kinase inhibitors have been recognized as promising candidates for the treatment of various cancers… 
2011
2011
Aristolochia manshuriensis has been used for centuries in Chinese medicinal system for their versatile medicinal uses. Recent… 
2010
2010
Background: Olomoucine II, the most recent derivative of roscovitine, is an exceptionally potent pharmacological inhibitor of… 
Highly Cited
2010
Highly Cited
2010
Embryonic stem cells (ESCs) proliferate rapidly and have a unique cell-cycle structure with a very short G1 phase. Previous… 
Highly Cited
2010
Highly Cited
2010
Nine geranylated flavanones isolated from the fruits of Paulownia tomentosa (4-12) and two from the roots of Morus alba (13 and… 
2009
2009
Olomoucine II is a cyclin-dependent kinase inhibitor and a potential antineoplastic agent because it can arrest animal cell… 
Highly Cited
2005
Highly Cited
2005
Abstract.The study describes the protein kinase selectivity profile, as well as the binding mode of olomoucine II in the… 
Highly Cited
2002
Highly Cited
2002
2001
2001
INTRODUCTION. The cell division cycle is controlled by cyclin-dependent kinases (cdk), which consist of a catalytic subunit (cdk1…